The Importance of Natural Anticoagulants in Ischemic Stroke

Oct 13, 2025 by thesweetdesigns.com 7 views

Protein Levels C, S Protein, and Antithrombin III in Acute Ischemic Stroke Patients at the Adam Malik Hajj Center General Hospital Medan

Introduction

Ischemic stroke is a clinical syndrome characterized by a rapid loss of brain function due to disorders of blood supply to the brain. This disorder is usually caused by ischemia, which is a lack of supply of glucose and oxygen due to thrombosis or embolism. In this context, the role of natural anticoagulants such as C protein, S protein, and Antitrombin III becomes very important. Although the existence and function of these three proteins is recognized in the process of controlling blood coagulation, information about their levels in cases of ischemic stroke is still minimal. Therefore, it is essential to observe the levels of C, S protein, and antithrombin III in patients before the ischemic stroke.

The Importance of Natural Anticoagulants in Ischemic Stroke

Natural anticoagulants play a crucial role in preventing blood clot formation and maintaining blood flow. C protein, S protein, and antithrombin III are three essential proteins that work together to regulate blood coagulation. C protein and S protein are involved in the coagulation cascade, while antithrombin III inhibits the activity of thrombin, a key enzyme in blood clot formation. Understanding the levels of these proteins in ischemic stroke patients can provide valuable insights into the pathophysiology of the disease and help develop effective prevention and treatment strategies.

Research Purposes

This study aims to determine the difference in protein levels C, S protein, and antithrombin III examined on days 1, 3, and 7 during acute ischemic stroke patients. The study was conducted at the Adam Malik Haji Hospital in Medan in the period January to May 2018, involving 21 patients with sampling three times.

Methodology

This study uses prospective longitudinal methods. Data is taken from 21 acute ischemic stroke patients, and sampling is carried out on days 1, 3, and 7. Measurement of protein levels C, protein S, and antithrombin III using A4 coatron tools, with chromogenic assay techniques for C and antithrombin III protein, and Clotting Assay for S protein.

Research Results

Of the 21 patients who participated, there were 12 male patients (57.1%) and 9 female patients (42.9%). The results of the analysis using the repeated anova test and the friedman test showed the absence of a significant difference in the level of C, S, and antithrombin III protein levels on the 1st, 3rd, and 7th day. The correlation test showed that each C protein, S protein, and antithrombin III have a significant positive relationship. However, between C protein and S protein and between C protein and antithrombin III do not show significant correlation, as well as S and antithrombin III protein.

Conclusion

Average levels of protein C, protein S, and antithrombin III do not show significant differences on days 1, 3, and 7. This shows that measurement of levels of these three proteins in a short time may not provide an accurate picture of the condition of the coagulation of stroke patients ischemic. This study recommends that sampling be carried out with a longer time span to obtain more valid and relevant data.

Implications and Added Value

Understanding the levels of protein C, S protein, and antithrombin III in the context of ischemic stroke are very important. This research is expected to provide a stronger basis for further research on the role of natural anticoagulants in ischemic stroke, and encourage the development of better prevention and therapy strategies. With an increase in understanding of these factors, it is expected to find a new approach to managing a more effective and efficient ischemic stroke.

Limitations of the Study

This study has several limitations. The sample size is relatively small, and the study was conducted in a single hospital. Additionally, the study only measured protein levels at three time points, which may not be sufficient to capture the dynamic changes in protein levels during ischemic stroke. Future studies should aim to recruit a larger sample size and measure protein levels at multiple time points to provide a more comprehensive understanding of the role of natural anticoagulants in ischemic stroke.

Future Directions

This study highlights the importance of natural anticoagulants in ischemic stroke and provides a foundation for further research in this area. Future studies should aim to investigate the relationship between protein levels and clinical outcomes in ischemic stroke patients. Additionally, studies should explore the potential therapeutic applications of natural anticoagulants in ischemic stroke, such as the use of antithrombin III as a potential treatment for ischemic stroke.

Conclusion

In conclusion, this study provides valuable insights into the levels of protein C, S protein, and antithrombin III in acute ischemic stroke patients. The results of this study suggest that measurement of protein levels in a short time may not provide an accurate picture of the condition of the coagulation of stroke patients ischemic. This study recommends that sampling be carried out with a longer time span to obtain more valid and relevant data. Future studies should aim to investigate the relationship between protein levels and clinical outcomes in ischemic stroke patients and explore the potential therapeutic applications of natural anticoagulants in ischemic stroke.
Frequently Asked Questions (FAQs) about Protein Levels C, S Protein, and Antithrombin III in Acute Ischemic Stroke Patients

Q: What is ischemic stroke?

A: Ischemic stroke is a clinical syndrome characterized by a rapid loss of brain function due to disorders of blood supply to the brain. This disorder is usually caused by ischemia, which is a lack of supply of glucose and oxygen due to thrombosis or embolism.

Q: What is the role of natural anticoagulants in ischemic stroke?

A: Natural anticoagulants, such as C protein, S protein, and antithrombin III, play a crucial role in preventing blood clot formation and maintaining blood flow. They work together to regulate blood coagulation and prevent the formation of blood clots that can cause ischemic stroke.

Q: What are the main differences between C protein, S protein, and antithrombin III?

A: C protein and S protein are involved in the coagulation cascade, while antithrombin III inhibits the activity of thrombin, a key enzyme in blood clot formation. C protein and S protein have a significant positive relationship, but between C protein and antithrombin III and between S and antithrombin III do not show significant correlation.

Q: What are the implications of this study?

A: This study provides a stronger basis for further research on the role of natural anticoagulants in ischemic stroke and encourages the development of better prevention and therapy strategies. With an increase in understanding of these factors, it is expected to find a new approach to managing a more effective and efficient ischemic stroke.

Q: What are the limitations of this study?

A: This study has several limitations, including a relatively small sample size and the study was conducted in a single hospital. Additionally, the study only measured protein levels at three time points, which may not be sufficient to capture the dynamic changes in protein levels during ischemic stroke.

Q: What are the future directions for research?

A: Future studies should aim to investigate the relationship between protein levels and clinical outcomes in ischemic stroke patients. Additionally, studies should explore the potential therapeutic applications of natural anticoagulants in ischemic stroke, such as the use of antithrombin III as a potential treatment for ischemic stroke.

Q: What are the potential therapeutic applications of natural anticoagulants in ischemic stroke?

A: Natural anticoagulants, such as antithrombin III, may have potential therapeutic applications in ischemic stroke, such as preventing blood clot formation and improving blood flow to the brain. However, further research is needed to fully understand the potential benefits and risks of using natural anticoagulants as a treatment for ischemic stroke.

Q: How can this study contribute to the development of better prevention and therapy strategies for ischemic stroke?

A: This study provides valuable insights into the levels of protein C, S protein, and antithrombin III in acute ischemic stroke patients. The results of this study suggest that measurement of protein levels in a short time may not provide an accurate picture of the condition of the coagulation of stroke patients ischemic. This study recommends that sampling be carried out with a longer time span to obtain more valid and relevant data.

Q: What are the potential benefits of using natural anticoagulants as a treatment for ischemic stroke?

A: The potential benefits of using natural anticoagulants as a treatment for ischemic stroke include preventing blood clot formation, improving blood flow to the brain, and reducing the risk of complications and mortality. However, further research is needed to fully understand the potential benefits and risks of using natural anticoagulants as a treatment for ischemic stroke.

Q: What are the potential risks of using natural anticoagulants as a treatment for ischemic stroke?

A: The potential risks of using natural anticoagulants as a treatment for ischemic stroke include bleeding complications, thrombocytopenia, and other adverse effects. However, further research is needed to fully understand the potential benefits and risks of using natural anticoagulants as a treatment for ischemic stroke.